US FDA approves Daiichi Sankyo-AstraZeneca’s Enhertu for lung cancer
The latest approval was based on the findings from the Phase II DESTINY-Lung02 trial of Enhertu.
Therapy Area
Latest in
Therapy Area
Ceapro and McMaster extend partnership to develop Covid-19 therapy
This assessment in experimental models of lung fibrosis will aid in progressing the technology into a Phase I clinical trial.
Alnylam identifies gene to lower abdominal fat and decrease cardiovascular risk
Alnylam aims to develop a therapy that targets the INHBE gene and reduces the overall risk of T2D and coronary…
By
GentiBio and BMS partner to develop inflammatory bowel disease therapies
BMS will make development and commercial milestone payments of up to $1.9bn to GentiBio.
FDA grants Orphan Drug status to Aro Biotherapeutics’ Pompe disease therapy
The company plans to advance ABX1100 into clinical trials in the middle of next year.
Gemini enters business combination deal with Disc Medicine
The proceeds will be utilised to advance the pipeline of Disc to clinical trials and provide runway into 2025.
Cerevance and Merck partner to detect new Alzheimer’s targets
Cerevance is entitled to receive development and commercial milestone payments of nearly $1.1bn.
Health Canada accepts Paladin’s NDS for epilepsy-linked seizure therapy
Discovered by SK Biopharmaceuticals and SK life science, cenobamate is a new small molecule anti-seizure therapy.